Audit of cervical cancer chemoradiation guideline compliance across National Cancer Grid centers
Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
This project will check how closely hospitals across India follow recommended chemoradiation treatments for patients with cervical cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 618 (estimated) |
| Sex | Female |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 2 sites (Mumbai, Maharashtra and 1 other locations) |
| Trial ID | NCT07290972 on ClinicalTrials.gov |
What this trial studies
This multicenter observational audit will collect de-identified retrospective and prospective data from participating National Cancer Grid institutions over a six-month period to document whether definitive, adjuvant, palliative radiation and concurrent chemotherapy meet guideline recommendations. Patients enrolled in other prospective treatment trials are excluded, while cases referred for brachytherapy alone are included. Data will be entered via a shared electronic case record form (Google e-form) that exports standardized outputs to facilitate pooled analysis and resource assessment. The initiative aims to map compliance, identify system-level gaps, and inform targeted implementation efforts across diverse resource settings in India.
Who should consider this trial
Good fit: Patients eligible are those with histologically proven cervical cancer who were planned to receive radical, adjuvant, or palliative radiation with or without concurrent or systemic chemotherapy, or who were referred for brachytherapy, during the participating center's six-month capture period.
Not a fit: Individual patients should not expect direct therapeutic benefit from participation, and patients enrolled in other prospective clinical trials are excluded from this audit.
Why it matters
Potential benefit: If successful, the audit could reveal gaps in care and guide quality-improvement efforts that improve adherence to guideline-based chemoradiation and thereby patient outcomes.
How similar studies have performed: Previous oncology audits and implementation programs have shown that systematic audits and guideline dissemination can improve adherence, though comprehensive nationwide compliance data for cervical chemoradiation in India remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned. Furthermore any cases referred to the institution for brachytherapy alone will also be included.
Where this trial is running
Mumbai, Maharashtra and 1 other locations
- Tata Memorial Hospital — Mumbai, Maharashtra, India (Recruiting)
- Tata Memorial Hospital — Mumbai, Maharashtra, India (Recruiting)
Study contacts
- Principal investigator: Dr. Supriya Chopra, MD — ACTREC, Tata Memorial Centre, Navi Mumbai India
- Study coordinator: Dr. Supriya Chopra, MD
- Email: supriyasastri@gmail.com
- Phone: 9930958309
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.